Abstract
Stable gastric pentadecapeptide BPC 157 (GEPPPGKPADDAGLV, M.W. 1419) may be the new drug stable in human gastric juice, effective both in the upper and lower GI tract, and free of side effects. BPC 157, in addition to an antiulcer effect efficient in therapy of inflammatory bowel disease (IBD) (PL 14736) so far only tested in clinical phase II, has a very safe profile, and exhibited a particular wound healing effect. It also has shown to interact with the NO-system, providing endothelium protection and angiogenic effect, even in severely impaired conditions (i.e., it stimulated expression of early growth response 1 gene responsible for cytokine and growth factor generation and early extracellular matrix (collagen) formation (but also its repressor nerve growth factor 1- A binding protein-2)), important to counteract severe complications of advanced and poorly controlled IBD. Hopefully, the lessons from animal studies, particularly advanced intestinal anastomosis healing, reversed short bowel syndrome and fistula healing indicate BPC 157s high significance in further IBD therapy. Also, this supportive evidence (i.e., no toxic effect, limit test negative, LD1 not achieved, no side effect in trials) may counteract the problems commonly exercised in the use of peptidergic agents, particularly those used on a long-term basis.
Keywords: BPC 157, intestinal anastomosis, short bowel, colocutaneous fistulas, inflammatory bowel disease, peptidergic agents, anastomosis, pentadecapeptide, antiulcer, clinical phase II
Current Medicinal Chemistry
Title: Focus on Ulcerative Colitis: Stable Gastric Pentadecapeptide BPC 157
Volume: 19 Issue: 1
Author(s): P. Sikiric, S. Seiwerth, R. Rucman, B. Turkovic, D. S. Rokotov, L. Brcic, M. Sever, R. Klicek, B. Radic, D. Drmic, S. Ilic, D. Kolenc, V. Stambolija, Z. Zoricic, H. Vrcic and B. Sebecic
Affiliation:
Keywords: BPC 157, intestinal anastomosis, short bowel, colocutaneous fistulas, inflammatory bowel disease, peptidergic agents, anastomosis, pentadecapeptide, antiulcer, clinical phase II
Abstract: Stable gastric pentadecapeptide BPC 157 (GEPPPGKPADDAGLV, M.W. 1419) may be the new drug stable in human gastric juice, effective both in the upper and lower GI tract, and free of side effects. BPC 157, in addition to an antiulcer effect efficient in therapy of inflammatory bowel disease (IBD) (PL 14736) so far only tested in clinical phase II, has a very safe profile, and exhibited a particular wound healing effect. It also has shown to interact with the NO-system, providing endothelium protection and angiogenic effect, even in severely impaired conditions (i.e., it stimulated expression of early growth response 1 gene responsible for cytokine and growth factor generation and early extracellular matrix (collagen) formation (but also its repressor nerve growth factor 1- A binding protein-2)), important to counteract severe complications of advanced and poorly controlled IBD. Hopefully, the lessons from animal studies, particularly advanced intestinal anastomosis healing, reversed short bowel syndrome and fistula healing indicate BPC 157s high significance in further IBD therapy. Also, this supportive evidence (i.e., no toxic effect, limit test negative, LD1 not achieved, no side effect in trials) may counteract the problems commonly exercised in the use of peptidergic agents, particularly those used on a long-term basis.
Export Options
About this article
Cite this article as:
Sikiric P., Seiwerth S., Rucman R., Turkovic B., S. Rokotov D., Brcic L., Sever M., Klicek R., Radic B., Drmic D., Ilic S., Kolenc D., Stambolija V., Zoricic Z., Vrcic H. and Sebecic B., Focus on Ulcerative Colitis: Stable Gastric Pentadecapeptide BPC 157, Current Medicinal Chemistry 2012; 19(1) . https://dx.doi.org/10.2174/092986712803414015
DOI https://dx.doi.org/10.2174/092986712803414015 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |

- Author Guidelines
- Editorial Policies
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Allegations from Whistleblowers
- Publishing Ethics and Rectitude
- Increase Visibility Of Your Article
- Archiving Policies
- Reviewer Guidelines
- Guest Editor Guidelines
- Board Recruitment Workflow
- Short Guide for New Editors
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Genetics and Heart Failure: A Concise Guide for the Clinician
Current Cardiology Reviews Subcutaneous Implantable Cardioverter Defibrillators: An Overview of Implantation Techniques and Clinical Outcomes
Current Cardiology Reviews Modulators of the Vascular Endothelin Receptor in Blood Pressure Regulation and Hypertension
Current Molecular Pharmacology Pharmacological Management Options to Prevent and Reduce Ischemic Hemorrhagic Transformation
Current Drug Targets Glycogen Synthase Kinase-β3 in Ischemic Neuronal Death
Current Neurovascular Research New Insight in Antiplatelet Therapy Monitoring in Cardiovascular Patients: From Aspirin to Thienopyridine
Cardiovascular & Hematological Disorders-Drug Targets Potential MicroRNA Targets for Cancer Chemotherapy
Current Medicinal Chemistry HtrA Protease Family as Therapeutic Targets
Current Pharmaceutical Design Hypertension - Current Natural Strategies to Lower Blood Pressure
Current Pharmaceutical Design Recent Updates on Current and Upcoming Biomarkers for Cardiovascular Diseases
Current Pharmaceutical Design Recent Advances and Patents on Circulatory Support Devices for Pediatric Patients
Recent Patents on Biomedical Engineering (Discontinued) Pharmacogenetic Variation and Metformin Response
Current Drug Metabolism Scaffolds for Bone Regeneration: State of the Art
Current Pharmaceutical Design Multitarget Drugs of Plants Origin Acting on Alzheimer's Disease
Current Medicinal Chemistry Strategies for Targeting Lentiviral Vectors
Current Gene Therapy Tumor Necrosis Factor Inhibitors as Therapeutic Choice in Psoriasis
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Cardiovascular Involvement in Pediatric Systemic Autoimmune Diseases: The Emerging Role of Noninvasive Cardiovascular Imaging
Inflammation & Allergy - Drug Targets (Discontinued) Neprilysin: A Potential Therapeutic Target of Arterial Hypertension?
Current Cardiology Reviews Patent Selections
Recent Patents on Cardiovascular Drug Discovery Gender Disparity in Lipid Target Achievements in High and Very High Atherosclerotic Cardiovascular Disease Risk Patients in the Arabian Gulf
Current Vascular Pharmacology